Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer4 Nov 2026

238 Off-the-shelf immune-shielded iPSC-derived armored CAR γδ T cells as a novel cell therapy to treat hepatocellular carcinoma

Philip Hublitz¹
Michael Esquerré²
Audrey Holtzinger³
Andreas Scheel³
Stephanie Sontag⁴
Tabea Erdmann¹
Judith Hartmann¹
Tommaso Pezzica¹
Jessica Nolte¹
Lea Renneberg¹
Stefanie Kober¹
Theresa Klisch¹

7 more authors

Thomas Aleyt¹
Marion Philippe⁵
Karine Pingris⁵
Celine Poussereau Pomie⁵
Caroline Stienne⁵
Katrin Ridders¹
Matthias Austen¹

5 affiliations

¹Evotec International GmbH, Goettingen, Germany
²2Evotec France SAS, Toulouse, France
³1Evotec International GmbH, Goettingen, Germany
⁴3Evotec International GmbH, Goettingen, Germany
⁵Evotec France SAS, Toulouse, France

Open at source DOI Cite

HepaKineticNet: Deep Learning of CT-Derived Intratumoral Heterogeneity for Overall Survival Prediction in BCLC Stage B-C Hepatocellular Carcinoma Treated with Locoregional Therapy Plus First-Line TKI and Anti-PD-1 Therapy.
Jinpeng Li, Wenzhe Bu, Xiaotian Hanming +3
Journal of hepatocellular carcinoma1 Oct 2026Peer-reviewedCC BY-NCFull textMedical imaging & radiologyEurope PMC
Associations of CT-Derived Body Composition with Textbook Outcomes and Early Death After Hepatectomy for Hepatocellular Carcinoma
Chuwen Chen, Qiwen Xiang, Jing Hu +2
Journal of clinical medicine28 Sep 2026Peer-reviewedCC BYFull textGeneral medicineEurope PMC
Adjuvant and Perioperative Systemic Therapy for Resectable Hepatocellular Carcinoma: Evidence, Biological Rationale, and Trial Design
Xin Xin, Ruoyu Miao
Cancers27 Sep 2026Peer-reviewedCC BYFull textOncologyEurope PMC
Cost-effectiveness analysis of penpulimab plus anlotinib versus sorafenib as first-line therapy for advanced hepatocellular carcinoma
Zhiwei Zheng, Lisheng Huang, Yuling Zhang +2
Immunotherapy4 Oct 2026Peer-reviewedLicence not statedFull textGeneral medicinePMC
Correlation between circulating tumor cell levels and tumor response in patients with advanced hepatocellular carcinoma undergoing immunotherapy and molecular targeted therapy
Jiangmin Zhou, Huifang Xiong, Honghao Zhou +2
Frontiers in oncology16 Oct 2026Peer-reviewedCC BYFull textOncologyEurope PMC

Cite

BibTeX RIS

BibTeX

@article{hublitz2026offtheshelf,
  title = {{238 Off-the-shelf immune-shielded iPSC-derived armored CAR γδ T cells as a novel cell therapy to treat hepatocellular carcinoma}},
  author = {Philip Hublitz and Michael Esquerré and Audrey Holtzinger and Andreas Scheel and Stephanie Sontag and Tabea Erdmann and Judith Hartmann and Tommaso Pezzica and Jessica Nolte and Lea Renneberg and Stefanie Kober and Theresa Klisch and Thomas Aleyt and Marion Philippe and Karine Pingris and Celine Poussereau Pomie and Caroline Stienne and Katrin Ridders and Matthias Austen},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0238},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0238},
  note = {CC BY},
}

RIS

TY  - JOUR
TI  - 238 Off-the-shelf immune-shielded iPSC-derived armored CAR γδ T cells as a novel cell therapy to treat hepatocellular carcinoma
AU  - Philip Hublitz
AU  - Michael Esquerré
AU  - Audrey Holtzinger
AU  - Andreas Scheel
AU  - Stephanie Sontag
AU  - Tabea Erdmann
AU  - Judith Hartmann
AU  - Tommaso Pezzica
AU  - Jessica Nolte
AU  - Lea Renneberg
AU  - Stefanie Kober
AU  - Theresa Klisch
AU  - Thomas Aleyt
AU  - Marion Philippe
AU  - Karine Pingris
AU  - Celine Poussereau Pomie
AU  - Caroline Stienne
AU  - Katrin Ridders
AU  - Matthias Austen
PY  - 2026
DA  - 2026/11/04
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0238
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0238
SN  - 2051-1426
ER  -

Related

Cite